131 studies found for:    prostate cancer, vaccine therapy
Show Display Options
Rank Status Study
1 Active, not recruiting Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Sargramostim (GM-CSF, Leukine);   Drug: Flutamide (Eulexin);   Biological: PROSTVAC-F/ TRICOM;   Biological: PROSTVAC-V/TRICOM
2 Completed Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: recombinant viral vaccine therapy;   Biological: sargramostim
3 Recruiting Vaccine Therapy in Curative Resected Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Biological: Dendritic cell vaccine
4 Withdrawn Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: GVAX prostate cancer vaccine;   Drug: bicalutamide;   Drug: goserelin;   Drug: leuprolide acetate
5 Recruiting Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: PROSTVAC-F/TRICOM;   Biological: PROSTVAC-V/TRICOM;   Drug: Enzalutamide (Xtandi)
6 Completed Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
7 Completed Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: recombinant interleukin-12
8 Unknown  Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: BCG vaccine;   Biological: prostate cancer vaccine ONY-P1;   Other: placebo
9 Not yet recruiting Biological Therapy With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Biological: glycosylated recombinant human interleukin-7;   Other: laboratory biomarker analysis
10 Completed Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: MUC-2-Globo H-KLH conjugate vaccine;   Biological: QS21
11 Unknown  Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: therapeutic autologous dendritic cells
12 Unknown  Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: incomplete Freund's adjuvant
13 Completed Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: recombinant fowlpox-prostate specific antigen vaccine;   Biological: recombinant vaccinia prostate-specific antigen vaccine;   Biological: recombinant vaccinia-B7.1 vaccine;   Biological: sargramostim;   Drug: docetaxel
14 Completed Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: GPI-0100;   Biological: MUC-2-Globo H-KLH conjugate vaccine
15 Completed
Has Results
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: sipuleucel-T;   Biological: Placebo
16 Completed Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: QS21;   Biological: TF(c)-KLH conjugate vaccine;   Biological: Thomsen-Friedenreich antigen;   Biological: keyhole limpet hemocyanin
17 Completed Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: aldesleukin;   Biological: recombinant fowlpox-prostate specific antigen vaccine;   Biological: recombinant vaccinia prostate-specific antigen vaccine;   Biological: recombinant vaccinia-B7.1 vaccine;   Biological: sargramostim;   Drug: nilutamide
18 Completed Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer
Interventions: Biological: PSA:154-163(155L) peptide vaccine;   Biological: incomplete Freund's adjuvant;   Other: laboratory biomarker analysis
19 Completed Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: MUC1-KLH vaccine/QS21
20 Completed Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: MUC-2-KLH vaccine;   Biological: QS21

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years